3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
41
Carcinoma, Non-Small-Cell Lung
28
Lung Neoplasms
8
Triple Negative Breast Neoplasms
6
Neoplasm Metastasis
6
Neoplasms
5
Uterine Cervical Neoplasms
4
Recurrence
2
Mesothelioma
2
Lymphoma, Non-Hodgkin
2
Carcinoma
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Thoracic Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Nonhematologic Malignancies
1
Non-Squamous Non-Small Cell Lung Cancer
1
Non - Small Cell Lung Cancer NSCLC
1
Neuroendocrine Tumors
1
NSCLC
1
Metatropic dwarfism
1
Metastatic HER2-positive Breast Cancer
1
Lung Diseases
1
Lethal Congenital Contracture Syndrome 2
1
HR+HER2- Breast Cancer
1
HER2-positive Advanced Breast Cancer
1
Desmoplastic Small Round Cell Tumor
1
Interventions
Carboplatin
9
Pemetrexed
7
pembrolizumab
4
osimertinib
3
entinostat
3
Gemcitabine
3
zipalertinib
2
selpercatinib
2
pralsetinib
2
durvalumab
2
camrelizumab
2
Paclitaxel
2
Erlotinib Hydrochloride
2
Cisplatin
2
Bronchoscopy
2
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
necitumumab
1
ficlatuzumab
1
exemestane
1
demcizumab
1
cobimetinib
1
ceralasertib
1
atezolizumab
1
alectinib
1
aflibercept
1
Vinorelbine
1
Toll-Like Receptor 1
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lung Diseases
×
Vinorelbine
×
Clear all
NCT05583188
2024-07-19
VIGOR
Galvanize Therapeutics, Inc.
Phase 4
Terminated
5 enrolled